valine has been researched along with Prostatic Neoplasms in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 18 (69.23) | 29.6817 |
| 2010's | 6 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, N; Cheng, L; Farah, E; Kong, Y; Lanman, NA; Li, C; Li, L; Liu, X; Lorenz, GR; Pascuzzi, P; Ratliff, T; Zhang, Y | 1 |
| Kamimura, R; Kawana, S; Nishisako, R; Urabe, T | 1 |
| Cui, D; Dai, J; Keller, ET; Keller, JM; Mizokami, A; Xia, S | 1 |
| Alajati, A; Alimonti, A; Arribas, A; Bertoni, F; Chen, J; D'Antuono, R; Delaleu, N; Dimitrov, M; Fraering, P; Gerber, H; Gnetti, L; Losa, M; Nepveu, A; Pasquini, E; Perciato, ML; Pinton, S; Revandkar, A; Rinaldi, A; Toso, A | 1 |
| Jurhill, RR; van der Veen, H; van Leenders, GJ; Verhagen, PC | 1 |
| Bowman, R; Jeffery, H; Khaw, KT; Lentjes, MA; Loh, YH; Luben, RN; Mitrou, PN; Rodwell, SA; Wood, A | 1 |
| Fan, WJ; Liu, T; Wang, HY; Wang, XH; Xu, XJ; Zhai, JX; Zhang, ZX; Zou, LW | 1 |
| Hakkarainen, A; Kaikkonen, J; Kallioniemi, OP; Lehtimäki, T; Marchesani, M; Matikainen, M; Pukkala, E; Salonen, JT; Schleutker, J; Seppälä, E; Tuomainen, TP; Uimari, P | 1 |
| Aguilar, L; Aguilar-Cordova, E; Ayala, G; Butler, EB; Caillouet, J; Carpenter, LS; Chiu, JK; Davis, M; Kadmon, D; Lu, HH; Mai, WY; Miles, B; Teh, BS; Thompson, T; Timme, TL; Vlachaki, MT; Wheeler, T; Woo, SY | 1 |
| Cross, JV; Templeton, DJ | 1 |
| Amato, R; Ayala, G; Butler, EB; Fujita, T; Gdor, Y; Kadmon, D; Kusaka, N; Mai, WY; Miles, BJ; Pramudji, CK; Satoh, T; Teh, BS; Thompson, TC; Timme, TL; Vlachaki, MT; Wheeler, T | 1 |
| Christensen, GB; Cunningham, JM; Debes, JD; Hebbring, SJ; Jacobsen, SJ; Liu, W; McDonnell, SK; Schaid, DJ; Thibodeau, SN; Tindall, DJ; Yokomizo, A | 1 |
| Bauer, ME; da Cruz, IB; de Andrade, VM; de Oliveira, G; do Canto, ME; dos Santos, AR; Peres, A; Sá, G; Taufer, M | 1 |
| Abrahamsson, PA; Ahlgren, G; Gadaleanu, V; Giwercman, A; Giwercman, YL | 1 |
| Arai, T; Hara, K; Honda, H; Hosoi, T; Ito, YM; Kadowaki, T; Kameyama, S; Kitamura, T; Mamun, MR; Ohta, N; Ozeki, T; Sawabe, M; Suzuki, M; Takahashi, S; Takeuchi, T; Yamada, Y; Yanagihara, Y | 1 |
| Burger, M; Denzinger, S; Hammerschmied, C; Hartmann, A; Maderstorfer, A; Stoehr, R; Tannapfel, A; Wieland, WF | 1 |
| Aguilar-Cordova, E; Butler, EB; Fattah, EA; Fujita, T; Kusaka, N; Mai, WY; Naruishi, K; Satoh, T; Teh, BS; Thompson, TC; Timme, TL | 1 |
| Fujisawa, M; Goda, K; Gotoh, A; Hara, I; Hinata, N; Kamidono, S; Shirakawa, T; Tanaka, K; Terao, S; Yamada, Y | 1 |
| Azzouzi, AR; Cancel-Tassin, G; Cormier, L; Cussenot, O; Fournier, G; Mangin, P; Nicolaiew, N; Valeri, A | 1 |
| Berndt, SI; Chanock, S; Chatterjee, N; Hayes, RB; Huang, WY; Kang, D; Lee, KM; Park, SK; Peters, U; Reding, D; Welch, R | 1 |
| Arai, T; Hosoi, T; Kitamura, T; Kurosaki, T; Sawabe, M; Suzuki, M | 1 |
| Chung, LW; Fuji, K; Fujisawa, M; Gardner, TA; Gotoh, A; Hamada, K; Hara, I; Higashihara, E; Hinata, N; Kamidono, S; Kao, C; Matsuo, M; Okegawa, T; Shirakawa, T; Sugimura, K; Takenaka, A; Tanaka, K; Terao, S | 1 |
| Bartsch, G; Cato, AC; Culig, Z; Hobisch, A; Klocker, H; Peterziel, H; Radmayr, C; Stober, J | 1 |
| Batter, S; Casey, D; Febbo, PG; Giovannucci, E; Hennekens, CH; Kantoff, PW; Platz, EA; Stampfer, MJ | 1 |
| Adler, HL; Aguilar-Cordova, E; Butler, EB; Herman, JR; Kadmon, D; Miles, BJ; Scardino, PT; Shalev, M; Teh, BS; Thompson, TC | 1 |
| Chu, W; Harvie, S; Ho, M; Jewett, MA; Nam, RK; Narod, SA; Sweet, J; Toi, A; Trachtenberg, J; Vesprini, D | 1 |
1 review(s) available for valine and Prostatic Neoplasms
| Article | Year |
|---|---|
No association between COMT Val158Met polymorphism and prostate cancer risk: a meta-analysis.
Topics: Catechol O-Methyltransferase; Genetic Predisposition to Disease; Humans; Male; Methionine; Polymorphism, Genetic; Prostatic Neoplasms; Risk Factors; Valine | 2013 |
7 trial(s) available for valine and Prostatic Neoplasms
| Article | Year |
|---|---|
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Topics: Acyclovir; Adenoviridae; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antiviral Agents; Biopsy; Combined Modality Therapy; Flutamide; Follow-Up Studies; Genetic Therapy; Genetic Vectors; Humans; Leuprolide; Male; Middle Aged; Prodrugs; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Thymidine Kinase; Valacyclovir; Valine | 2004 |
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
Topics: Acyclovir; Adenoviridae; Adult; Aged; Aged, 80 and over; Antiviral Agents; Avian Sarcoma Viruses; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Ganciclovir; Genetic Therapy; Humans; Lymphocyte Activation; Male; Middle Aged; Prodrugs; Prostatectomy; Prostatic Neoplasms; Thymidine Kinase; Valacyclovir; Valine | 2004 |
Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients.
Topics: Acyclovir; Adenoviridae; Aged; Aged, 80 and over; Androgen Antagonists; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Genetic Therapy; Humans; Immunity, Cellular; Killer Cells, Natural; Male; Middle Aged; Prostatic Neoplasms; Radiotherapy, Intensity-Modulated; Thymidine Kinase; Valacyclovir; Valine | 2006 |
Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.
Topics: Acyclovir; Adenoviridae; Aged; Antiviral Agents; Bone Neoplasms; Genetic Therapy; Hospitals, University; Humans; Japan; Male; Middle Aged; Osteocalcin; Prostatic Neoplasms; Thymidine Kinase; Valacyclovir; Valine | 2006 |
Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study.
Topics: Aged; Alanine; Alleles; Antioxidants; Case-Control Studies; Diet; Exons; Free Radical Scavengers; Genetic Variation; Humans; Isoenzymes; Male; Middle Aged; Polymorphism, Genetic; Prostatic Neoplasms; Risk Factors; Smoking; Superoxide Dismutase; Superoxide Dismutase-1; Valine; Vitamin E; White People | 2007 |
Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.
Topics: Acyclovir; Adenoviridae; Aged; Androgen Antagonists; Antineoplastic Agents; Antiviral Agents; Bone and Bones; Bone Neoplasms; Docetaxel; Genetic Therapy; Genetic Vectors; Humans; Male; Middle Aged; Osteocalcin; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography; Taxoids; Thymidine Kinase; Valacyclovir; Valine | 2007 |
The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Anticarcinogenic Agents; Aspirin; beta Carotene; Boston; Double-Blind Method; Heart Diseases; Humans; Isoenzymes; Leucine; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Prostatic Neoplasms; Risk Factors; Valine; White People | 1999 |
18 other study(ies) available for valine and Prostatic Neoplasms
| Article | Year |
|---|---|
NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.
Topics: Animals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptor, Notch1; Receptor, Notch2; Signal Transduction; Tetrahydronaphthalenes; Transcription Factor HES-1; Valine; Xenograft Model Antitumor Assays | 2019 |
[Case of drug-induced angioedema (DIAE) on induction of anesthesia with difficult ventilation due to oropharyngeal edema].
Topics: Aged; Anesthesia, Epidural; Anesthesia, General; Angioedema; Angiotensin Receptor Antagonists; Edema; Humans; Intubation, Intratracheal; Male; Pharyngeal Diseases; Prostatectomy; Prostatic Neoplasms; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2014 |
Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Inbred NOD; NF-kappa B; Prostatic Neoplasms; Signal Transduction; Taxoids; Tetrahydronaphthalenes; Valine; Xenograft Model Antitumor Assays | 2015 |
Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
Topics: ADAM17 Protein; Amyloid Precursor Protein Secretases; Animals; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p27; Humans; Male; Mice; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Notch; Signal Transduction; Tetrahydronaphthalenes; Up-Regulation; Valine | 2016 |
Reduction of serum prostate-specific antigen levels following varicella-zoster infection and valaciclovir treatment in prostate cancer.
Topics: Acyclovir; Aged; Antiviral Agents; Herpes Zoster; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Valacyclovir; Valine | 2009 |
MGMT Ile143Val polymorphism, dietary factors and the risk of breast, colorectal and prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study.
Topics: Adult; Aged; Breast Neoplasms; Colorectal Neoplasms; Diet; DNA Modification Methylases; DNA Repair Enzymes; Female; Genotype; Humans; Isoleucine; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Prostatic Neoplasms; Risk Factors; Tumor Suppressor Proteins; Valine | 2010 |
New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men.
Topics: Aged; Alleles; Aryldialkylphosphatase; Case-Control Studies; Esterases; Finland; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genotype; Heterozygote; Humans; Incidence; Isoleucine; Male; Middle Aged; Mutation; Odds Ratio; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prospective Studies; Prostatic Neoplasms; Risk Assessment; Risk Factors; Sampling Studies; Valine | 2003 |
Oxidative stress inhibits MEKK1 by site-specific glutathionylation in the ATP-binding domain.
Topics: Adenosine Triphosphate; Alkylation; Amino Acid Sequence; Amino Acid Substitution; Binding Sites; Catalytic Domain; Cell Line, Tumor; Cysteine; Dithiothreitol; Enzyme Inhibitors; Ethylmaleimide; Glutathione; Humans; Lymph Nodes; Male; MAP Kinase Kinase Kinase 1; Molecular Sequence Data; Mutation; Oxidants; Oxidation-Reduction; Oxidative Stress; Peptides; Prostatic Neoplasms; Protein Structure, Tertiary; Valine | 2004 |
Gluthatione-S-transferase P1 polymorphism I105V in familial and sporadic prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Codon; Cohort Studies; Family Health; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Heterozygote; Homozygote; Humans; Isoenzymes; Isoleucine; Japan; Male; Middle Aged; Odds Ratio; Polymorphism, Genetic; Prostatic Neoplasms; United States; Valine | 2004 |
Is the Val16Ala manganese superoxide dismutase polymorphism associated with the aging process?
Topics: Adult; Aged; Aged, 80 and over; Aging; Alanine; Antigens, CD; Breast Neoplasms; Cause of Death; DNA Damage; Female; Free Radical Scavengers; Free Radicals; Gene Frequency; Genotype; Humans; Infant, Newborn; Male; Middle Aged; Oxidative Stress; Polymorphism, Genetic; Prostatic Neoplasms; Risk Factors; Superoxide Dismutase; Valine | 2005 |
The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Aged; Alanine; Alleles; Arginine; Biomarkers, Tumor; Case-Control Studies; Dihydrotestosterone; Disease Progression; Follow-Up Studies; Genetic Predisposition to Disease; Genotype; Glutamine; Humans; Leucine; Luteinizing Hormone; Male; Middle Aged; Point Mutation; Polymorphism, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Androgen; Risk Factors; Sex Hormone-Binding Globulin; Sweden; Terminal Repeat Sequences; Testosterone; Threonine; Valine | 2005 |
The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Catechol O-Methyltransferase; Disease Progression; Disease-Free Survival; Estramustine; Genetic Predisposition to Disease; Genotype; Humans; Male; Methionine; Middle Aged; Polymorphism, Genetic; Prodrugs; Prostate-Specific Antigen; Prostatic Neoplasms; Valine | 2005 |
Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Topics: Aged; Alleles; DNA Mutational Analysis; DNA, Neoplasm; Enzyme Activation; Exons; Female; Genome, Human; Glutamine; Humans; Immunohistochemistry; Male; Microsatellite Instability; Middle Aged; Mitogen-Activated Protein Kinases; Mutation; Polymerase Chain Reaction; Prostatic Neoplasms; Proto-Oncogene Proteins B-raf; Signal Transduction; Valine | 2006 |
Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Amino Acid Substitution; Chemoprevention; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Genetic Variation; Genotype; Humans; Lysine; Male; Prostatic Neoplasms; Treatment Failure; Valine | 2007 |
The Val158Met polymorphism of the catechol-O-methyltransferase gene is not associated with the risk of sporadic or latent prostate cancer in Japanese men.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Asian People; Catechol O-Methyltransferase; Humans; Japan; Male; Methionine; Middle Aged; Polymorphism, Single Nucleotide; Prostatic Neoplasms; Risk Factors; Valine | 2007 |
Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding.
Topics: Amino Acid Sequence; Androgen Antagonists; Animals; Base Sequence; Binding Sites; Flutamide; Haplorhini; Ligands; Male; Methionine; Molecular Sequence Data; Mutation; Prostatic Neoplasms; Protein Binding; Protein Conformation; Receptors, Androgen; Structure-Activity Relationship; Transcriptional Activation; Transfection; Valine | 1995 |
Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.
Topics: Acyclovir; Adenoviridae; Antiviral Agents; Clinical Trials as Topic; Defective Viruses; Ganciclovir; Genetic Therapy; Genetic Vectors; Humans; Injections, Intralesional; Male; Prostatic Neoplasms; Simplexvirus; Thymidine Kinase; Valacyclovir; Valine; Virus Replication | 2000 |
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.
Topics: Aged; Alleles; Cholestenone 5 alpha-Reductase; Disease Progression; Follow-Up Studies; Genetic Markers; Humans; Leucine; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Odds Ratio; Oxidoreductases; Phenotype; Polymorphism, Genetic; Prostatic Neoplasms; Valine | 2001 |